Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma

Ludek Raida, Tomas Papajik, Zuzana Rusinakova, Vit Prochazka, Edgar Faber, Dana Cahova, Pavel Tucek, Karel Indrak
2014 Biomedical Papers of the Faculty of Medicine of Palacky University  
Aims. A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods. A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and < 90%). Reduced RDI in two groups (90-99% and < 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of
more » ... e probability of complete remission (CR), disease relapse, eventfree survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared. Results. Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13). Conclusion. We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients.
doi:10.5507/bp.2013.022 pmid:23579110 fatcat:iaf2m3peurg5pn4k2ne7ge24wa